Short-Term Debt to Equity Ratio: Annexon, Inc. (ANNX)

Annexon, Inc. (ANNX) is developing biopharmaceuticals in neurology, a field where massive testing expenditures are replaced by monopoly profits following FDA certification, as evidenced by the asset's market value of 0.02 shown on this chart. The business relies on an expensive "cold chain" transportation system to ensure drug stability. C1q patents and the complexity of clinical stages create an exceptionally high barrier to entry.

To assess the fundamental stability of Annexon, Inc. (ANNX), analyzing the borrowing structure is critically important. This indicator is calculated as the ratio of liabilities with a maturity of over one year to total equity. The dynamics of the short-term debt-to-equity ratio demonstrate the level of financial leverage and the business's margin of safety. This is particularly significant for biopharmaceuticals, where massive clinical trial expenditures require strict control over the debt load.